Sign In
Buy RGLS
$8.16
+0 (+0%)
At Close: Sep 24, 2025
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..
12:05pm, Wednesday, 25'th Jun 2025
Novartis AG (SWX:NOVN) submitted a written non-binding indication of interest to acquire Regulus Therapeutics Inc. (NasdaqCM:RGLS) for approximately $200 million on April 4, 2025. Novartis AG (SWX:NOV
Novartis completes acquisition of Regulus Therapeutics
09:13am, Wednesday, 25'th Jun 2025
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of com
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
07:56am, Tuesday, 27'th May 2025
Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
04:05pm, Thursday, 08'th May 2025
Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right ("CVR") upon the
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
02:10pm, Wednesday, 30'th Apr 2025
NEW YORK , April 30, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
12:24pm, Wednesday, 30'th Apr 2025
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
11:22am, Wednesday, 30'th Apr 2025
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders
09:00am, Wednesday, 30'th Apr 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus shareh
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
07:41am, Wednesday, 30'th Apr 2025
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to l
Novartis to buy Regulus Therapeutics for up to $1.7 billion
07:25am, Wednesday, 30'th Apr 2025
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceut
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
07:00am, Wednesday, 30'th Apr 2025
Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximate
Should You Buy Regulus (RGLS) After Golden Cross?
10:55am, Thursday, 24'th Apr 2025
Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out above
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
08:00am, Wednesday, 02'nd Apr 2025
SAN DIEGO , April 2, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (th
